

World Journal of *Clinical Cases*

World J Clin Cases 2022 September 16; 10(26): 9180-9549



Contents

Thrice Monthly Volume 10 Number 26 September 16, 2022

REVIEW

- 9180** Assisting individuals with diabetes in the COVID-19 pandemic period: Examining the role of religious factors and faith communities

Eseadi C, Ossai OV, Onyishi CN, Ilechukwu LC

- 9192** Role of octreotide in small bowel bleeding

Khedr A, Mahmoud EE, Attallah N, Mir M, Boike S, Rauf I, Jama AB, Mushtaq H, Surani S, Khan SA

MINIREVIEWS

- 9207** Internet of things-based health monitoring system for early detection of cardiovascular events during COVID-19 pandemic

Dami S

- 9219** Convergence mechanism of mindfulness intervention in treating attention deficit hyperactivity disorder: Clues from current evidence

Xu XP, Wang W, Wan S, Xiao CF

- 9228** Clinical presentation, management, screening and surveillance for colorectal cancer during the COVID-19 pandemic

Akbulut S, Hargura AS, Garzali IU, Aloun A, Colak C

- 9241** Early diagnostic value of liver stiffness measurement in hepatic sinusoidal obstruction syndrome induced by hematopoietic stem cell transplantation

Tan YW, Shi YC

ORIGINAL ARTICLE

Case Control Study

- 9254** Local inflammatory response to gastroesophageal reflux: Association of gene expression of inflammatory cytokines with esophageal multichannel intraluminal impedance-pH data

Morozov S, Sentsova T

Retrospective Study

- 9264** Evaluation of high-risk factors and the diagnostic value of alpha-fetoprotein in the stratification of primary liver cancer

Jiao HB, Wang W, Guo MN, Su YL, Pang DQ, Wang BL, Shi J, Wu JH

- 9276** One-half layer pancreaticojejunostomy with the rear wall of the pancreas reinforced: A valuable anastomosis technique

Wei JP, Tai S, Su ZL

- 9285** Development and validation of an epithelial-mesenchymal transition-related gene signature for predicting prognosis

Zhou DH, Du QC, Fu Z, Wang XY, Zhou L, Wang J, Hu CK, Liu S, Li JM, Ma ML, Yu H

Observational Study

- 9303** Incidence and risk factor analysis for swelling after apical microsurgery

Bi C, Xia SQ, Zhu YC, Lian XZ, Hu LJ, Rao CX, Jin HB, Shang XD, Jin FF, Li JY, Zheng P, Wang SH

CASE REPORT

- 9310** Acute carotid stent thrombosis: A case report and literature review

Zhang JB, Fan XQ, Chen J, Liu P, Ye ZD

- 9318** Congenital ovarian anomaly manifesting as extra tissue connection between the two ovaries: A case report

Choi MG, Kim JW, Kim YH, Kim AM, Kim TY, Ryu HK

- 9323** Cefoperazone-sulbactam and ornidazole for *Gardnerella vaginalis* bloodstream infection after cesarean section: A case report

Mu Y, Li JJ, Wu X, Zhou XF, Tang L, Zhou Q

- 9332** Early-onset ophthalmoplegia, cervical dyskinesia, and lower extremity weakness due to partial deletion of chromosome 16: A case report

Xu M, Jiang J, He Y, Gu WY, Jin B

- 9340** Posterior mediastinal extralobar pulmonary sequestration misdiagnosed as a neurogenic tumor: A case report

Jin HJ, Yu Y, He W, Han Y

- 9348** Unexpected difficult airway due to severe upper tracheal distortion: A case report

Zhou JW, Wang CG, Chen G, Zhou YF, Ding JF, Zhang JW

- 9354** Special epithelioid trophoblastic tumor: A case report

Wang YN, Dong Y, Wang L, Chen YH, Hu HY, Guo J, Sun L

- 9361** Intrahepatic multicystic biliary hamartoma: A case report

Wang CY, Shi FY, Huang WF, Tang Y, Li T, He GL

- 9368** ST-segment elevation myocardial infarction in Kawasaki disease: A case report and review of literature

Lee J, Seo J, Shin YH, Jang AY, Suh SY

- 9378** Bilateral hypocalcaemic cataracts due to idiopathic parathyroid insufficiency: A case report

Li Y

- 9384** Single organ hepatic artery vasculitis as an unusual cause of epigastric pain: A case report

Kaviani R, Farrell J, Dehghan N, Moosavi S

- 9390** Congenital lipoid adrenal hyperplasia with Graves' disease: A case report

Wang YJ, Liu C, Xing C, Zhang L, Xu WF, Wang HY, Wang FT

- 9398** Cytokine release syndrome complicated with rhabdomyolysis after chimeric antigen receptor T-cell therapy: A case report
Zhang L, Chen W, Wang XM, Zhang SQ
- 9404** Antiphospholipid syndrome with renal and splenic infarction after blunt trauma: A case report
Lee NA, Jeong ES, Jang HS, Park YC, Kang JH, Kim JC, Jo YG
- 9411** Uncontrolled high blood pressure under total intravenous anesthesia with propofol and remifentanyl: A case report
Jang MJ, Kim JH, Jeong HJ
- 9417** Noncirrhotic portal hypertension due to peripheral T-cell lymphoma, not otherwise specified: A case report
Wu MM, Fu WJ, Wu J, Zhu LL, Niu T, Yang R, Yao J, Lu Q, Liao XY
- 9428** Resumption of school after lockdown in COVID-19 pandemic: Three case reports
Wang KJ, Cao Y, Gao CY, Song ZQ, Zeng M, Gong HL, Wen J, Xiao S
- 9434** Complete recovery from segmental zoster paresis confirmed by magnetic resonance imaging: A case report
Park J, Lee W, Lim Y
- 9440** Imaging findings of immunoglobulin G4-related hypophysitis: A case report
Lv K, Cao X, Geng DY, Zhang J
- 9447** Systemic lupus erythematosus presenting with progressive massive ascites and CA-125 elevation indicating Tjasma syndrome? A case report
Wang JD, Yang YF, Zhang XF, Huang J
- 9454** Locally advanced cervical rhabdomyosarcoma in adults: A case report
Xu LJ, Cai J, Huang BX, Dong WH
- 9462** Rapid progressive vaccine-induced immune thrombotic thrombocytopenia with cerebral venous thrombosis after ChAdOx1 nCoV-19 (AZD1222) vaccination: A case report
Jiang SK, Chen WL, Chien C, Pan CS, Tsai ST
- 9470** Burkitt-like lymphoma with 11q aberration confirmed by needle biopsy of the liver: A case report
Yang HJ, Wang ZM
- 9478** Common carotid artery thrombosis and malignant middle cerebral artery infarction following ovarian hyperstimulation syndrome: A case report
Xu YT, Yin QQ, Guo ZR
- 9484** Postoperative radiotherapy for thymus salivary gland carcinoma: A case report
Deng R, Li NJ, Bai LL, Nie SH, Sun XW, Wang YS
- 9493** Follicular carcinoma of the thyroid with a single metastatic lesion in the lumbar spine: A case report
Chen YK, Chen YC, Lin WX, Zheng JH, Liu YY, Zou J, Cai JH, Ji ZQ, Chen LZ, Li ZY, Chen YX

- 9502** Guillain-Barré syndrome and hemophagocytic syndrome heralding the diagnosis of diffuse large B cell lymphoma: A case report
Zhou QL, Li ZK, Xu F, Liang XG, Wang XB, Su J, Tang YF
- 9510** Intravitreal injection of conbercept for bullous retinal detachment: A case report
Xiang XL, Cao YH, Jiang TW, Huang ZR
- 9518** Supratentorial hemangioblastoma at the anterior skull base: A case report
Xu ST, Cao X, Yin XY, Zhang JY, Nan J, Zhang J

META-ANALYSIS

- 9524** Certain sulfonylurea drugs increase serum free fatty acid in diabetic patients: A systematic review and meta-analysis
Yu M, Feng XY, Yao S, Wang C, Yang P

LETTER TO THE EDITOR

- 9536** Glucose substrate in the hydrogen breath test for gut microbiota determination: A recommended noninvasive test
Xie QQ, Wang JF, Zhang YF, Xu DH, Zhou B, Li TH, Li ZP
- 9539** A rare cause of acute abdomen after a Good Friday
Pante L, Brito LG, Franciscatto M, Brambilla E, Soldera J
- 9542** Obesity is associated with colitis in women but not necessarily causal relationship
Shen W, He LP, Zhou LL
- 9545** Risk stratification of primary liver cancer
Tan YW

ABOUT COVER

Editorial Board Member of *World Journal of Clinical Cases*, Youngmin Oh, MD, PhD, Associate Professor, Neurosurgeon, Department of Neurosurgery, Jeonbuk National University Medical School/Hospital, Jeonju 54907, Jeollabukdo, South Korea. timoh@jbnu.ac.kr

AIMS AND SCOPE

The primary aim of *World Journal of Clinical Cases* (WJCC, *World J Clin Cases*) is to provide scholars and readers from various fields of clinical medicine with a platform to publish high-quality clinical research articles and communicate their research findings online.

WJCC mainly publishes articles reporting research results and findings obtained in the field of clinical medicine and covering a wide range of topics, including case control studies, retrospective cohort studies, retrospective studies, clinical trials studies, observational studies, prospective studies, randomized controlled trials, randomized clinical trials, systematic reviews, meta-analysis, and case reports.

INDEXING/ABSTRACTING

The WJCC is now abstracted and indexed in Science Citation Index Expanded (SCIE, also known as SciSearch®), Journal Citation Reports/Science Edition, Current Contents®/Clinical Medicine, PubMed, PubMed Central, Scopus, Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstar Journals Database. The 2022 Edition of Journal Citation Reports® cites the 2021 impact factor (IF) for WJCC as 1.534; IF without journal self cites: 1.491; 5-year IF: 1.599; Journal Citation Indicator: 0.28; Ranking: 135 among 172 journals in medicine, general and internal; and Quartile category: Q4. The WJCC's CiteScore for 2021 is 1.2 and Scopus CiteScore rank 2021: General Medicine is 443/826.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: Hua-Ge Yin; Production Department Director: Xu Guo; Editorial Office Director: Jin-Lei Wang.

NAME OF JOURNAL

World Journal of Clinical Cases

ISSN

ISSN 2307-8960 (online)

LAUNCH DATE

April 16, 2013

FREQUENCY

Thrice Monthly

EDITORS-IN-CHIEF

Bao-Gan Peng, Jerzy Tadeusz Chudek, George Kontogeorgos, Maurizio Serati, Ja Hyeon Ku

EDITORIAL BOARD MEMBERS

<https://www.wjgnet.com/2307-8960/editorialboard.htm>

PUBLICATION DATE

September 16, 2022

COPYRIGHT

© 2022 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS

<https://www.wjgnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjgnet.com/bpg/GerInfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjgnet.com/bpg/gerinfo/240>

PUBLICATION ETHICS

<https://www.wjgnet.com/bpg/GerInfo/288>

PUBLICATION MISCONDUCT

<https://www.wjgnet.com/bpg/gerinfo/208>

ARTICLE PROCESSING CHARGE

<https://www.wjgnet.com/bpg/gerinfo/242>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjgnet.com/bpg/GerInfo/239>

ONLINE SUBMISSION

<https://www.f6publishing.com>



Noncirrhotic portal hypertension due to peripheral T-cell lymphoma, not otherwise specified: A case report

Miao-Miao Wu, Wen-Jun Fu, Jia Wu, Lin-Lin Zhu, Ting Niu, Rong Yang, Jin Yao, Qiang Lu, Xiao-Yang Liao

Specialty type: Medicine, general and internal

Provenance and peer review:

Unsolicited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's scientific quality classification

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

P-Reviewer: Cheng J; Salimi M, Iran

Received: April 25, 2022

Peer-review started: April 25, 2022

First decision: June 8, 2022

Revised: June 20, 2022

Accepted: August 5, 2022

Article in press: August 5, 2022

Published online: September 16, 2022



Miao-Miao Wu, Wen-Jun Fu, Jia Wu, Lin-Lin Zhu, Rong Yang, Xiao-Yang Liao, General Practice Ward/International Medical Center Ward, General Practice Medical Center, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China

Ting Niu, Department of Haematology, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China

Jin Yao, Department of Radiology, West China Hospital of Sichuan University, Chengdu 610041, Sichuan Province, China

Qiang Lu, Department of Ultrasound, West China Hospital of Sichuan University, Chengdu 610041, Sichuan Province, China

Corresponding author: Xiao-Yang Liao, MS, Chief Physician, Professor, General Practice Ward/International Medical Center Ward, General Practice Medical Center, West China Hospital, Sichuan University, No. 37 GuoXueXiang Street, Chengdu 610041, Sichuan Province, China. liaoxyang@wchscu.cn

Abstract

BACKGROUND

Peripheral T-cell lymphoma (PTCL), an aggressive and rare disease that belongs to a heterogeneous group of mature T-cell lymphomas, develops rapidly and has a poor prognosis. Early detection and treatment are essential to improve patient cure and survival rates. Here, we report a rare case of PTCL with clinical presentation of noncirrhotic portal hypertension, which provides a basis for early vigilance of lymphomas in the future.

CASE SUMMARY

A 65-year-old Chinese woman was admitted to our hospital because of abdominal distension for 3 months and pitting oedema of both lower limbs for 2 months. Physical examinations and associated auxiliary examinations showed the presence of hepatosplenomegaly, and her hepatic venous pressure gradient was 10 mmHg. Immunohistochemical analysis of the liver biopsy confirmed the diagnosis of PTCL. The patient underwent combination therapy with dexamethasone, VP-16, and chidamide. Unfortunately, after 41 days of chemotherapy, the patient died of multiple organ failure.

CONCLUSION

PTCL accompanied by noncirrhotic portal hypertension is rarely reported. This

case report discusses the diagnosis of a patient according to the literature.

Key Words: Noncirrhotic portal hypertension; Ascites; Peripheral T-cell lymphoma; Lymphoma; Chidamide; Case report

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: Peripheral T-cell lymphoma (PTCL) is an aggressive and rare disease that belongs to a heterogeneous group of mature T-cell lymphomas, and is classified as PTCL, not otherwise specified (PTCL-NOS). It is the most common type and most often involves nodal sites; however, many patients present with extranodal involvement, including the liver, bone marrow, gastrointestinal tract, and skin. The clinical presentations of PTCL are lymphadenopathy syndrome and B symptoms (night sweats, fever, and weight loss). Noncirrhotic portal hypertension, hydrothorax and ascites can also occur in rare cases, and noncirrhotic portal hypertension and ascites are less common as first symptoms. Here, we report a rare case of a patient with PTCL who presented with noncirrhotic portal hypertension.

Citation: Wu MM, Fu WJ, Wu J, Zhu LL, Niu T, Yang R, Yao J, Lu Q, Liao XY. Noncirrhotic portal hypertension due to peripheral T-cell lymphoma, not otherwise specified: A case report. *World J Clin Cases* 2022; 10(26): 9417-9427

URL: <https://www.wjgnet.com/2307-8960/full/v10/i26/9417.htm>

DOI: <https://dx.doi.org/10.12998/wjcc.v10.i26.9417>

INTRODUCTION

Peripheral T-cell lymphoma (PTCL) is an aggressive and rare disease that belongs to a heterogeneous group of mature T-cell lymphomas, and is classified as PTCL not otherwise specified (PTCL-NOS). It is the most common type and most often involves nodal sites; however, many patients present with extranodal involvement, including the liver, bone marrow, gastrointestinal tract, and skin[1]. The clinical presentations of PTCL are lymphadenopathy syndrome and B symptoms (night sweats, fever, and weight loss). Noncirrhotic portal hypertension, hydrothorax, and ascites can also occur in rare cases [2,3], and noncirrhotic portal hypertension and ascites are less common as first symptoms. Here, we report a rare case of a patient with PTCL who presented with noncirrhotic portal hypertension.

CASE PRESENTATION

Chief complaints

A 65-year-old Chinese woman was referred to our hospital due to abdominal distension for over 3 months and pitting oedema of both lower limbs for over 2 mo.

History of present illness

Approximately 3 mo previously, this patient was admitted to a local hospital due to abdominal distension. Additional symptoms included pitting oedema of both lower limbs, anorexia and melena, and the patient lost 5 kg in two months. The patient had no jaundice, fever, or night sweats. Ultrasonography (US) indicated that she had neither oesophageal nor gastric varices or ulcers. but gastroscopic examination showed external compression of large gastric curvature, the cause of gastric wall compression is unknown, taking into account the left side of lying stomach bend side close to the spleen. Extra-hospital computed tomography (CT) showed hepatosplenomegaly and no other lesions around the stomach. So we think the growth of the spleen is the most likely reason for the external pressure of the greater curvature of the stomach. After 10 days of albumin infusion therapy, the above symptoms were not relieved but rather further aggravated. Therefore, she was referred to a tertiary hospital.

History of past illness

She had no history of hepatitis and no significant past medical history.

Physical examination

The physical examination revealed that the patient had abdominal varices and an increase in abdominal circumference to 98 cm.

Laboratory examinations

Laboratory tests showed that her white blood cell count was $1.80 \times 10^9/\text{L}$ (reference value $3.5\text{--}9.5 \times 10^9/\text{L}$), the neutrophil count was $1.33 \times 10^9/\text{L}$ (reference value $1.8\text{--}6.3 \times 10^9/\text{L}$), the neutrophil percentage was 73.80% (reference value 40%-75%), haemoglobin was 71 g/L (reference value 115-150 g/L), platelet count was $54 \times 10^9/\text{L}$ (reference value $100\text{--}300 \times 10^9/\text{L}$), albumin was 26.5 g/L (reference value 40.0-55.0 g/L), lactate dehydrogenase (LDH) was 347 IU/L (reference value 120-250 IU/L), and liver and renal function were within normal limits. Her erythrocyte sedimentation rate was 3.0 mm/h (reference value < 38 mm/h). Coagulation function revealed a prothrombin time of 18.2 s (reference value 9.6-12.8 s), and fibrinogen was 0.64 g/L (reference value 2.0-4.0 g/L) (Table 1). Tests for Epstein-Barr virus, tuberculosis, and hepatitis B, A, C, D, and E were all negative.

Imaging examinations

Positron emission tomography-CT (PET) indicated hepatosplenomegaly and swelling of the peritoneum, mesentery, descending duodenum, and horizontal segments (Figure 1). Liver ultrasound showed increased liver volume; no cirrhosis-specific nodular changes were observed, and liver stiffness was measured at 19.55 kPa (Figure 2). CT also showed an enlarged liver volume, parenchymal density, and acceptable strengthening, as well as a small, tiny cyst. Two sides of the intrahepatic portal vein showed no enhancement of the low-density strip, showing a "double-track sign". Consideration was given to the possibility of intrahepatic lymphatic stasis. Liver computed tomographic arteriography showed hepatosplenomegaly without portal vein, splenic vein, or mesenteric arteriovenous thrombosis (Figure 3).

FURTHER DIAGNOSTIC WORK-UP

Relevant laboratory data for ascites were as follows: appearance was yellow and cloudy, nucleated cells were $40 \times 10^6/\text{L}$, red blood cells were $6700 \times 10^6/\text{L}$, albumin was 25.3 g/L, glucose was 6.85 mmol/L, LDH was 246 IU/L, serum-ascites LDH gradient was 0.87, adenosine deaminase was 27.8 IU/L, the serum-ascites albumin gradient (SAAG) was 1.3, the ascitic fluid bacterial culture showed no bacterial growth, and the tuberculosis antibody test was negative. The hepatic venous pressure gradient (HVPG) measured by transjugular intrahepatic portosystemic shunt (TIPS) was 10 mmHg.

Ascites immunocytology showed that the lymphocyte population composition was approximately 93.3% nucleated cells, of which approximately 14.5% were weakly positive for CD5. Immunohistochemistry staining showed that the lymphocytes were positive for CD2, CD3, CD7, CD8, CD56, CD57, and T-cell receptor (TCR) $\alpha\beta$ but negative for CD11c, CD16, CD4, and TCR $\gamma\delta$. Because of the limitation of the medical technique used, DNA ploidy analysis of the exfoliated cells of the benign and malignant hydrothorax as well as flow cytometry of the ascites were not performed. Immunohistochemical analysis, performed on a bone marrow biopsy and aspiration (Figure 4), showed that cells were positive for CD3, CD7, and CD56 and negative for CD20, CD2, CD5, CD4, CD8, TIA-1, CD30, and CD34, as well as for Epstein-Barr virus-encoded RNAs, using in situ hybridization. Medical examination of ascites and bone marrow revealed a T-cell lymphoma. HVPG was measured by TIPS, liver biopsy was performed, and immunohistochemistry was performed. Macroscopically, 4 strips of grey yellow cord-like tissue, approximately 0.8-1.3 cm in length and 0.1 cm in diameter, were positive for CD3, CD5, CD7, CD8, CD43, CD56, TIA-1, and Ki-67 and negative for CD2, CD20, CD4, CD30, CD34, and TdT (Figure 5). Gene rearrangements are seen in the TCR γ low amplification peak (Table 2).

FINAL DIAGNOSIS

Eventually, after twenty days, the patient was diagnosed with an aggressive T-cell lymphoma (stage IV), which was categorised as a PTCL-NOS.

TREATMENT

The patient was diagnosed with T-cell lymphoma and was given 5 mg dexamethasone once a day. After four days of hormone therapy, the patient's oedema of both lower extremities was alleviated, but the reduction was not obvious; therefore, 25 mg etoposide once a week was added. After two days, the oedema of both lower limbs was significantly improved; however, ascitic changes were unremarkable. After 12 days, the patient was put on chidamide chemotherapy at the recommended starting dose of 20 mg, 1 to 3 times per week, 20 to 50 mg each time; the patient took the medication for 22 days with a cumulative dose of 110 mg, and the oedema of both lower limbs disappeared completely; however, ascites remained unchanged.

Table 1 Main laboratory test results

Laboratory tests	Result	Reference value
White blood cell count	$1.80 \times 10^9/L$	$3.5-9.5 \times 10^9/L$
Neutrophil count	$1.33 \times 10^9/L$	$1.8-6.3 \times 10^9/L$
Neutrophil percentage	0.738	40-75%
Haemoglobin	71 g/L	115-150 g/L
Platelet count	$54 \times 10^9/L$	$100-300 \times 10^9/L$
Albumin	26.5 g/L	40.0-55.0 g/L
Lactate dehydrogenase	347 IU/L	120-250 IU/L
Erythrocyte sedimentation rate	3.0 mm/h	< 38 mm/h
Coagulation function revealed a prothrombin time of	18.2 s	9.6-12.8 s
Fibrinogen	0.64 g/L	2.0-4.0 g/L


Table 2 Immunohistochemistry of pleural fluid, ascites, liver, and bone marrow

Parameter	Marrow	Ascites	Hydrothorax	Liver
CD2	++	+	+	-
CD3	++	++	+	+
CD4	-	-	-	-
CD5		+	+	+
CD7	++	++	++	+
CD8	+	+	++	+
CD11c	-	-		
CD16	-	+	-	
CD30				-
CD34				-
CD38		-	++	
CD43				+
CD45		+		
CD56	++	++	++	+
CD57	+	+p	++	
TCR $\alpha\beta$	+	+		
TCR $\gamma\delta$	-	-		
TIA-1				-
TDT				-
Ki-67				+

“+” indicates positive, the number indicates positive degree; “-” indicates negative; blank indicates that the examination was not performed.


OUTCOME AND FOLLOW-UP

The patient's international prognostic index was 5, which meant that she was in the high-risk group with a low 5-year survival rate[4]. Chidamide has a slower onset of action, and over the course of her treatment, her ascites did not improve. Unfortunately, after 41 d of chemotherapy, the patient died of multiple organ failure.



DOI: 10.12998/wjcc.v10.i26.9417 Copyright ©The Author(s) 2022.

Figure 1 Positron emission tomography. A: whole body scan; B and C: Scan showing the liver (SUVmax 2.28, mean 1.90). The liver was diffusely enlarged, increased spleen volume was observed, and there was a small amount of abdominal effusion.




DOI: 10.12998/wjcc.v10.i26.9417 Copyright ©The Author(s) 2022.

Figure 2 Liver ultrasound. A: The liver capsule was less smooth, and the right liver had a maximum oblique transaxial distance of 15 cm and increased parenchymal echogenicity. The liver parenchyma was slightly thickened and heterogeneous without a definite space-occupying lesion; B: The diameter of the extrahepatic portal vein was approximately 12 mm, and the blood flow was unidirectional to the liver at a flow rate of 29.3 cm/s. The cava caliber and lumen appeared normal, as did blood flow in the hepatic vein, superior mesenteric vein, splenic vein, and inferior vena cava.


DISCUSSION

PTCL is an aggressive and rare disease that belongs to a heterogeneous group of mature T-cell lymphomas that constitute less than 15% of all non-Hodgkin lymphomas in adults[5,6]. The most common symptoms included lymphadenopathy and B symptoms (night sweats, fever, and weight loss). The initial findings in the patient were portal hypertension, ascites, splenomegaly, and routine biochemistry of ascites showing no infection. SAAG was 1.3, and HVPg was 10 mmHg. Ultrasound and CT showed hepatosplenomegaly and liver cirrhosis. CTA showed that there was no obstruction or



DOI: 10.12998/wjcc.v10.i26.9417 Copyright ©The Author(s) 2022.


Figure 3 Liver computed tomographic arteriography. A: Spleen growth: spleen enhancement was less uniform, and patchy slightly hypointense areas were seen, not excluding infarcts or intrahepatic lymphatic stasis; B: The main portal vein and splenic vein were slightly thickened, the diameter of the main portal vein was approximately 1.5 cm, and there was no thrombus or collateral circulation opening, A and B: The vessel was smooth and unobstructed.



DOI: 10.12998/wjcc.v10.i26.9417 Copyright ©The Author(s) 2022.

Figure 4 Pathology and immunochemistry were performed on four pieces of liver tissue. A: Histopathological examination by haematoxylin and eosin staining (100 ×); B: Histopathological examination by haematoxylin and eosin staining (400×) showed few hepatocytes that were watery and lipomatous and multiple small focal lymphoid cell infiltrates; C: Immunochemical staining shows CD3 positivity; D: Immunochemical staining shows CD7 positivity. H&E, haematoxylin and eosin.

compression of blood vessels before and after the trunk. Therefore, we excluded prehepatic and posthepatic portal hypertension and focused on intrahepatic portal hypertension[7], and the patient's intrahepatic lymphatic stasis confirmed this speculation[8]. Although all examinations of our patients showed cirrhosis, the patient's liver was enlarged, so we had to doubt the accuracy of the examination. To our knowledge, the gold standard for cirrhosis is liver biopsy, which can be performed for diagnostic



DOI: 10.12998/wjcc.v10.i26.9417 Copyright ©The Author(s) 2022.

Figure 5 Pathology and immunochemistry of bone marrow. A: Histopathological examination by haematoxylin and eosin staining (100 ×); B: Histopathological examination by haematoxylin and eosin staining (400×) shows nucleated cells actively proliferating and replacing most of the adipose tissue, with more red blood cells than granulocytes and 2–4 megakaryocytes/hpf. The pathology showed that the bone marrow was nucleated and cell proliferation was active; C: Immunochemical staining shows CD3 positivity; D: Immunochemical staining shows CD7 positivity. H&E, haematoxylin and eosin; HPF, high power field.

purposes when the diagnosis is uncertain. Before they are properly diagnosed, most patients are misdiagnosed as having hepatic cirrhosis, potentially delaying treatment. Consequently, the patient was subjected to a liver biopsy which confirmed the absence of cirrhosis; thus, this presentation was either PTCL or NOS (Figure 6).

Portal hypertension is a rare manifestation in lymphomas. By searching cases of PTCL-related portal hypertension and ascites (Table 3), we found that only one report[9] described a T-cell lymphoma patient presenting with portal hypertension and oesophageal and gastric varices but no ascites and whose diagnosis was confirmed by splenectomy. Four cases[10-13] mentioned ascites, but none reported whether there was portal hypertension and only reported diagnosis by ascites flow cytometry. The mechanism of portal hypertension is not mentioned in the above cases. We speculate that the reason for the noncirrhotic portal hypertension in this patient was intrahepatic portal hypertension caused by the obstruction of a portal venous return due to intrahepatic lymph stasis. At the same time, visceral hyperdynamic circulation is one of the causes of increased portal blood flow and thus increased portal venous system pressure[14-16]. This case may be due to increased liver blood flow caused by tumours resulting in visceral hyperdynamic circulation leading to liver enlargement and portal hypertension. These two mechanisms together led to the development of noncirrhotic portal hypertension in this patient.

In the relevant literature, most patients are diagnosed based on ascites flow patterns, but in this case, due to insufficient sampling, the ascites flow pattern could not be successfully made. TIPS was used to perform portal pressure measurement and liver biopsy in this patient, and the diagnosis was finally made based on the biopsy results. TIPS is an interventional radiotherapy technique developed in the past 20 years. It uses the internal jugular vein as the puncture entrance, inserts the catheter through the superior vena cava, right atrium, and inferior vena cava, and inserts the hepatic vein into the hepatic vein under the guidance of an X-ray. Establishing an artificial shunt channel between them can not only measure the portal venous pressure to achieve the purpose of diagnosis but also reduce portal hypertension and achieve the purpose of treatment[17-19]. TIPS has been widely used for the diagnosis and treatment of portal hypertension[20]. TIPS is considered to be a successful and efficacious procedure with a 90% success rate[21,22]. Although there are unavoidable risks, recent studies have shown a high efficacy of TIPS compared to other treatments and presented an acceptable complication rate[23,24]. Research has shown that TIPS placement can be used for noncirrhotic portal hypertension [25]. At the same time, TIPS can also be used for liver biopsy to obtain a pathological diagnosis. When the patient was diagnosed with portal hypertension by TIPS, a liver biopsy was also performed, which

Table 3 A summary of demographic, radiographic, and clinical information from a review of five previously published cases of T-cell lymphomas with ascites and/or portal hypertension manifestations

Ref.	Age, Gender	Course of disease	Clinical Symptoms	Supplementary Examination	Biopsy Source	Immunohistochemistry	Diagnosis	Invasion of other parts	Treatment	Prognosis
Ameri[13]	61, F	2 ⁺ W	Abdominal discomfort	Ascites, hepatosplenomegaly	Ascites	CD4(+), CD2(+), CD5(+), CD3(+), CD7(-), CD16(-), CD56(-), CD57(-), TdT(-)	PTCL, NOS	Bone marrow	No treatment	NA
Yamamoto [10]	72, W	3 ⁺ W	Abdominal discomfort	Hydrothorax and ascites	Ascites	CD2 (+), CD3(+) (+),CD45(+), CD4 (-), CD8 (-)	PTCL	Thorax and abdomen	Cyclophosphamide, mitoxantrone, vincristine, etoposide, bleomycin, and prednisolone	Died of multiple organ failure
Izban[12]	76, F		Abdominal tenderness	Ascites, splenomegaly	Ascites	CD2(+), CD3(+), CD5(+), CD7(+), CD45(+), CD4(-), CD8(-)	PTCL	Bone marrow, liver	CHOP chemotherapy	Recurrence after chemotherapy
VakarLópez [11]	49, W	3 ⁺ M	Abdominal tenderness	Ascites	Ascites	CD3(+)	PTCL, NOS		No treatment	NA
Lindor[9]	65, F	2 ⁺ Y	Pectoralgia, esophageal and gastric variceal bleeding (EGVB)	Splenomegaly, EGVB	spleen	NA	Diffuse mixed-type T-cell lymphoma		Splenectomy	Bone marrow infiltration occurred 1 + year after the operation


PTCL: Peripheral T-cell lymphoma; NOS: Not otherwise specified.

was the key to the final diagnosis of the patient.

Therefore, when noncirrhotic portal hypertension is the main manifestation, all examinations suggest liver cirrhosis, but imaging does not conform to the characteristics of liver cirrhosis, such as liver enlargement. TIPS examination can be considered, which can not only measure portal pressure but also perform a biopsy to achieve the purpose of diagnosis, and the examination risk is relatively low. This study is helpful to reduce the missed diagnosis rate of lymphoma. PTCL-NOS has a poor prognosis, and the commonly used CHOP regimen is not effective[26-29]. Chidamide also takes at least 4 weeks to take effect. Early diagnosis can lead to more treatment opportunities and increase the prognosis of patients.

CONCLUSION

In conclusion, we describe a PTCL case presenting with ascites and noncirrhotic portal hypertension. Cases of noncirrhotic portal hypertension in PTCL are rare. When the clinical signs and auxiliary examinations suggest liver cirrhosis, as long as there is noncompliance with liver cirrhosis (hepatosplenomegaly), we should be alert to the possibility of other causes, such as lymphoma, reducing missed diagnosis of lymphoma.



DOI: 10.12998/wjcc.v10.i26.9417 Copyright ©The Author(s) 2022.

Figure 6 Diagnosis flow charts. PTCL: Peripheral T-cell lymphoma; CT: Computed tomography; CTA: Computed tomography angiography; SAAG: Serum-ascites albumin gradient; PET-CT: Positron emission tomography-CT.

FOOTNOTES

Author contributions: Liao XY designed and performed the research; Wu MM analysed the data and wrote the paper; Wu J, Niu T, and Fu WJ cared for the patient, designed and analysed the research, and helped with writing the paper; Zhu LL, and Yang R participated in revising the manuscript; Lu Q carried out the ultrasound; Yao J performed imaging studies; all authors have read and approved the final manuscript.

Informed consent statement: Informed written consent was obtained from the patient for publication of this report and any accompanying images.

Conflict-of-interest statement: The authors declare that they have no conflict of interest to disclose.

CARE Checklist (2016) statement: The authors have read the CARE Checklist. (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

Country/Territory of origin: China

ORCID number: Miao-Miao WU 0000-0003-3035-9914; Lin-Lin Zhu 0000-0002-4740-2838; Ting Niu 0000-0003-1580-1014; Jin Yao 0000-0002-4464-7143; Qiang Lu 0000-0002-4057-1997; Xiao-Yang Liao 0000000344099674.

S-Editor: Ma YJ

L-Editor: A

P-Editor: Ma YJ

REFERENCES

- Oluwasanjo A**, Kartan S, Johnson W, Alpdogan O, Gru A, Mishra A, Haverkos BM, Gong J, Porcu P. Peripheral T-Cell Lymphoma, not Otherwise Specified (PTCL-NOS). *Cancer Treat Res* 2019; **176**: 83-98 [PMID: [30596214](#) DOI: [10.1007/978-3-319-99716-2_4](#)]
- Das DK**. Serous effusions in malignant lymphomas: a review. *Diagn Cytopathol* 2006; **34**: 335-347 [PMID: [16604559](#) DOI: [10.1002/dc.20432](#)]
- Attanoos R**. Lymphoproliferative conditions of the serosa. *Arch Pathol Lab Med* 2012; **136**: 268-276 [PMID: [22372903](#) DOI: [10.5858/arpa.2011-0150-SA](#)]
- Sonnen R**, Schmidt WP, Müller-Hermelink HK, Schmitz N. The International Prognostic Index determines the outcome of patients with nodal mature T-cell lymphomas. *Br J Haematol* 2005; **129**: 366-372 [PMID: [15842660](#) DOI: [10.1111/j.1365-2141.2005.05478.x](#)]
- Vega F**. Pathology and Pathogenesis of T-Cell Lymphoma. *Clin Lymphoma Myeloma Leuk* 2020; **20** Suppl 1: S89-S93 [PMID: [32862884](#) DOI: [10.1016/S2152-2650\(20\)30474-2](#)]
- Vega F**, Amador C, Chadburn A, Feldman AL, Hsi ED, Wang W, Medeiros LJ. American Registry of Pathology Expert Opinions: Recommendations for the diagnostic workup of mature T cell neoplasms. *Ann Diagn Pathol* 2020; **49**: 151623 [PMID: [32947231](#) DOI: [10.1016/j.anndiagpath.2020.151623](#)]
- Carrier P**, Jacques J, Debette-Gratien M, Legros R, Sarabi M, Vidal E, Sautereau D, Bezanahary H, Ly KH, Loustaud-Ratti V. [Non-cirrhotic ascites: pathophysiology, diagnosis and etiology]. *Rev Med Interne* 2014; **35**: 365-371 [PMID: [24406314](#) DOI: [10.1016/j.revmed.2013.12.001](#)]
- Rajesh K**, Mukund A, Sureka B, Bansal K, Ronot M, Arora A. Non-cirrhotic portal hypertension: an imaging review. *Abdom Radiol (NY)* 2018; **43**: 1991-2010 [PMID: [29564495](#) DOI: [10.1007/s00261-018-1570-8](#)]
- Lindor K**, Rakela J, Perrault J, Van Heerden J. Noncirrhotic portal hypertension due to lymphoma. Reversal following splenectomy. *Dig Dis Sci* 1987; **32**: 1056-1058 [PMID: [3497789](#) DOI: [10.1007/BF01297199](#)]
- Yamamoto Y**, Kitajima H, Sakihana H, Shigeki T, Fukuhara S. CD3+CD4-CD8-TCR-alpha-beta+ T-cell lymphoma with clinical features of primary effusion lymphoma: an autopsy case. *Int J Hematol* 2001; **74**: 442-446 [PMID: [11794701](#) DOI: [10.1007/BF02982089](#)]
- Vakar-López F**, Yang M. Peripheral T-cell lymphoma presenting as ascites: a case report and review of the literature. *Diagn Cytopathol* 1999; **20**: 382-384 [PMID: [10352913](#) DOI: [10.1002/\(sici\)1097-0339\(199906\)20:6<382::aid-dc11>3.0.co;2-1](#)]
- Izbán KF**, Pooley RJ Jr, Selvaggi SM, Alkan S. Cytologic diagnosis of peripheral T-cell lymphoma manifesting as ascites. A case report. *Acta Cytol* 2001; **45**: 385-392 [PMID: [11393071](#) DOI: [10.1159/000327635](#)]
- Ameri MD**, Parekh TM, Qian YW, Elghetany MT, Schnadig V, Nawgiri R. A case of peripheral T-cell lymphoma, not otherwise specified in a HCV and HTLV-II-positive patient, diagnosed by abdominal fluid cytology. *J Gastrointest Oncol* 2016; **7**: S96-S99 [PMID: [27034820](#) DOI: [10.3978/j.issn.2078-6891.2015.054](#)]
- Vuppalanchi R**, Mathur K, Pyko M, Samala N, Chalasani N. Liver Stiffness Measurements in Patients with Noncirrhotic Portal Hypertension-The Devil Is in the Details. *Hepatology* 2018; **68**: 2438-2440 [PMID: [30014586](#) DOI: [10.1002/hep.30167](#)]
- Khanna R**, Sarin SK. Noncirrhotic Portal Hypertension: Current and Emerging Perspectives. *Clin Liver Dis* 2019; **23**: 781-807 [PMID: [31563222](#) DOI: [10.1016/j.cld.2019.07.006](#)]
- Da BL**, Koh C, Heller T. Noncirrhotic portal hypertension. *Curr Opin Gastroenterol* 2018; **34**: 140-145 [PMID: [29465431](#) DOI: [10.1097/MOG.0000000000000433](#)]
- Bucsics T**, Lampichler K, Vierziger C, Schoder M, Wolf F, Bauer D, Simbrunner B, Hartl L, Jachs M, Scheiner B, Trauner M, Gruenberger T, Karnel F, Mandorfer M, Reiberger T. Covered Transjugular Intrahepatic Portosystemic Shunt Improves Hypersplenism-Associated Cytopenia in Cirrhosis. *Dig Dis Sci* 2022 [PMID: [35301618](#) DOI: [10.1007/s10620-022-07443-6](#)]
- Artru F**, Moschouri E, Denys A. Direct intrahepatic portocaval shunt (DIPS) or transjugular transcaval intrahepatic portosystemic shunt (TTIPS) to treat complications of portal hypertension: Indications, technique, and outcomes beyond Budd-Chiari syndrome. *Clin Res Hepatol Gastroenterol* 2022; **46**: 101858 [PMID: [34999250](#) DOI: [10.1016/j.clinre.2022.101858](#)]
- Madhusudhan KS**, Sharma S, Srivastava DN. Percutaneous radiological interventions of the portal vein: a comprehensive review. *Acta Radiol* 2022; 2841851221080554 [PMID: [35187977](#) DOI: [10.1177/02841851221080554](#)]
- Wang C**, Liu J, Yao J, Ju S, Wang Y, Yang C, Bai Y, Yao W, Li T, Chen Y, Huang S, Xiong B. Transjugular intrahepatic portosystemic shunt in patients with autoimmune hepatitis-induced cirrhosis and variceal bleeding. *Abdom Radiol (NY)* 2022; **47**: 1464-1472 [PMID: [35230498](#) DOI: [10.1007/s00261-022-03465-w](#)]
- Tandon B**, Ramachandran J, Narayana S, Muller K, Pathi R, Wigg AJ. Outcomes of transjugular intrahepatic portosystemic shunt procedures: a 10-year experience. *J Med Imaging Radiat Oncol* 2021; **65**: 655-662 [PMID: [33687155](#) DOI: [10.1111/1754-9485.13168](#)]
- Grewal S**, Sidhu R, Elhassan M. Rings Flying Around: A rare complication of Transjugular Intrahepatic Portosystemic Shunt. *Respir Med Case Rep* 2022; **36**: 101586 [PMID: [35242514](#) DOI: [10.1016/j.rmcr.2022.101586](#)]
- Lee HL**, Lee SW. The role of transjugular intrahepatic portosystemic shunt in patients with portal hypertension: Advantages and pitfalls. *Clin Mol Hepatol* 2022; **28**: 121-134 [PMID: [34571587](#) DOI: [10.3350/cmh.2021.0239](#)]
- Qiu Z**, Zhu W, Yan H, Wang G, Zuo M, Qi H, Jiang W, Xue J, Zhang F, Gao F. Single-Centre Retrospective Study Using Propensity Score Matching Comparing Left Versus Right Internal Jugular Vein Access for Transjugular Intrahepatic Portosystemic Shunt (TIPS) Creation. *Cardiovasc Intervent Radiol* 2022; **45**: 563-569 [PMID: [34973068](#) DOI: [10.1007/s00270-021-03023-9](#)]
- Shreve LA**, O'Leary C, Clark TWI, Stavropoulos SW, Soulen MC. Transjugular intrahepatic portosystemic shunt for the management of symptomatic malignant pseudocirrhosis. *J Gastrointest Oncol* 2022; **13**: 279-287 [PMID: [35284108](#) DOI: [10.21037/jgo-21-501](#)]

- 26 **Liu W**, Ji X, Song Y, Wang X, Zheng W, Lin N, Tu M, Xie Y, Ping L, Ying Z, Zhang C, Deng L, Wu M, Feng F, Leng X, Sun Y, Du T, Zhu J. Improving survival of 3760 patients with lymphoma: Experience of an academic center over two decades. *Cancer Med* 2020; **9**: 3765-3774 [PMID: [32281275](#) DOI: [10.1002/cam4.3037](#)]
- 27 **Iżykowska K**, Rassek K, Korsak D, Przybylski GK. Novel targeted therapies of T cell lymphomas. *J Hematol Oncol* 2020; **13**: 176 [PMID: [33384022](#) DOI: [10.1186/s13045-020-01006-w](#)]
- 28 **Foster C**, Kuruvilla J. Treatment approaches in relapsed or refractory peripheral T-cell lymphomas. *F1000Res* 2020; **9** [PMID: [32934797](#) DOI: [10.12688/f1000research.22257.1](#)]
- 29 **Allen PB**, Pro B. Therapy of Peripheral T Cell Lymphoma: Focus on Nodal Subtypes. *Curr Oncol Rep* 2020; **22**: 44 [PMID: [32297075](#) DOI: [10.1007/s11912-020-00902-1](#)]



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-3991568

E-mail: bpgoffice@wjgnet.com

Help Desk: <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

